medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2015, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (3)

Methodology and applications of flow cytometry for immunophenotyping of acute leukemias

Marsán SV, del Valle PLO, Díaz DG, Macías AC

Language: Spanish
References: 32
Page: 242-253
PDF size: 175.83 Kb.


ABSTRACT

Flow cytometry (FCM) is an advanced, highly sensitive and automated technique used for immunophenotyping of normal and leukemic cells. The main methodological aspects to consider for better development and interpretation of immunophenotyping by FCM are shown in this article. Among them are: type, quantity, storage and transportation of the sample, use of anticoagulants, use of monoclonal antibodies and fluorochromes, erythrocyte lysate, cell attachment, calibration and auto-fluorescence compensation. Finally, the main applications of this methodology are given for defining the state of leukemic cell maturation, acute leukemias rank in different immunological subtypes, poor prognosis subgroups and to identify and detect aberrant phenotypes, which are useful for the diagnosis of minimal residual disease, allowing to stratify patients into different risk groups and thus to identify the anti-leukemic treatment.


REFERENCES

  1. Hedley B, Keeney M. Technical issues: flow cytometry and rare event analysis. Int J Lab Hem. 2013;35:344-50.

  2. Van Dongen JJ, Lhermitte L, Bottcher S, Ameida J, van der Velden VH, Flores- Montero J, et al. Euro Flow antibodies panels for standardized n-dimensional flow citometric immunophenotyping of normal, reactive and malignant leucocytes. Leukemia. 2012;26:1908-75.

  3. Donnenberg AD, Donnenberg VS. Rare event analysis in flow cytometry. Clin Lab Med. 2007;27:627-52.

  4. Drenon B, Fardel O, Fauchet R, Amiot J. Flow cytometry: application for the diagnosis and the follow-up of hematological malignancies. Ann Biol Clin. 2002 Nov- Dec;60(6):663-72.

  5. Yu G, Vergara N, Moore E, King R. Use of Flow Cytometry in the Diagnosis of Lymphoproliferative Disorders in Fluid Specimens. Diagn Cytopathol. 2014;42(8):664-70.

  6. Vogt RF Jr, Whitfield WE, Henderson LO, Hannon WH. Fluorescence intensity calibration for immunophenotyping by flow cytometry. Methods. 2000 Jul;21(3):289-96.

  7. Dongen JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and diseaseinduced shifts. Cytometry B Clin Cytom. 2004;60:1-13.

  8. vanLochem EG, van dV V, Wind HK, Marvelde JG, Westerdaal NA, van Craig FE. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111:3941-67.

  9. Orfao A, Ortuno F, De Santiago M, Lopez A, San Miguel J. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry. 2004;58:62-71.

  10. Gerardo CJ, Rodríguez C, Sastre D, Heller V, Fernández E. Utilización estratégica de CD45 en la identificación de células blásticas por citometría de flujo. Acta Bioquím Clín Latinoam. 2006;40(2):173-80.

  11. Orfao A, Ramudo L, López A, Rivas R, González M, Flores J, et al. Inmunofenotipaje de hemopatías malignas: de la investigación básica a la práctica asistencial. Haematologica. 2008;93(Extra 1):79-93.

  12. Marsán V, del Valle BB, Sánchez M, Macías C, Mazorra Z, Lam RM. Validación del ultramicrométodo inmunocitoquímico (UMICIQ) para el inmunofenotipaje de la leucemia linfoide aguda pediátrica. Rev Cubana Hematol Inmunol Hemoter. 2012;28(3):282-8.

  13. Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report on the second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. Cytometry B Clin Cytom. 2006;70:39-44

  14. Ahmadi A, Poorphatollad A, Aghaiipour M, Rezaei M, Nikoo-ghoftar M, Gharib A. Diagnostic value of CD117 in differential diagnosis of acute leukemia. Tumor Biol. 2014;35:6763-8.

  15. Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W. Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European Leukemia Net Work Package 10. Leukemia. 2011;25:567-74.

  16. Carey JL, McCoy JP, Keren DF. Flow cytometry in clinical diagnosis. 4thed. Chicago:ASCP Press; 2007.

  17. Stetler-Stevenson M, Davis B, Wood B, Braylan R. 2006 Bethesda International Consensus Conference on Flow Cytometry Immunophenotyping of Hematolymphoid Neoplasia. Cytometry B Clin Cytom. 2007;72B:S3.

  18. Nguyen D, Diamond LW, Braylan RC. Flow cytometry in hematopathology: a visual approach to data analysis and interpretation.2nd ed. Totowa:Human Press; 2007.

  19. Sedek L, Bulsa A, Sonsola A, Twardoch M, Wiccorck M, Malinowska L. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: How different are they from their normal counterpart? Cytometry. 2014;868:329-39.

  20. Craig F, Foon K. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941-67.

  21. Finn W, Carter K, Raich R, StoolmanL, Hero A. Analysis of Clinical Flow Cytometric Immunophenotyping Data by Clustering on Statistical Manifolds: Treating Flow Cytometry Data as High-Dimensional Objects. Cytometry. 2009:1-7.

  22. Dong HY, Kung J, Bhardwaj V, Mc Gilln J. Flow cytometry rapidly identifies all acute promielocytic leukemias with high specificity independent of underlying cytogenetic abnormalities. Am J Pathol. 2011;13574-84.

  23. Biomed A, Path Z, Comm S, Path S. Antigen expression pattern of acute promyelocytic leukaemia cases in Malasya. Med J Malasya. 2014;69(2):64-9.

  24. Borowitz MJ. Mixed phenotype acute leukemia. Cytometry B Clin Cytom. 2014;86:152-3.

  25. Gajendra S, Sachdev R, Dorwal P, Goel S, Jha B, Sahni T. Mixed-phenotypic acute leukemia: cytochemically myeloid and phenotypically early T-cell precursor acute lymphoblastic leukemia. Blood Res. 2014 Sep;49(3):196-8. doi: 10.5045/br.2014.49.3.196.

  26. Deffis M, Alvarado M, Ruiz G, Rosas A, Barrera G, Aguayo A. Diagnosing and treating mixed phenotype acute leukemia: a multicenter 10-year experience in Mexico. Ann Hematol. 2014;93:595-601.

  27. Ahmadzadeh A, Saedi S, Jaseb K, Asnafi A, Alghasi A, Saki N. T-cell acute lymphoblastic leukemia with del (7) (q11.2q22) and aberrant expression of myeloid markers. Int J Hematol Oncol Stem Cell Res. 2013;7(4):40-4.

  28. Gaipa G, Basso G, Alliprandi S, Migliacacca M, Vallinoto G, Maglia O, et al. Prednisone induces immunophenotipyc modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom. 2008;74:50-5.

  29. Yu G, Vergara N, Moore E, King R. Use of flow cytometry in the diagnosis of lymphoproliferative disorders in fluid specimens. Diagn Cytopathol. 2014;42(8):664-70.

  30. Schrappe M. Minimal residual disease: optical methods, timing, and clinical relevance for an individual patient. Hematology Am Soc Hematol Educ Program. 2012;2012:137-42. doi: 10.1182/asheducation-2012.1.137.

  31. Gaipa G, Basso G, Biondi A, Campana D. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Cytometry. 2013;84B:359-69.

  32. Salari F, Shahjahani M, Shahrabi S, Saki N. Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches. Med Oncol. 2014;31:2-9.




2020     |     www.medigraphic.com